AGEN

Equity

Agenus Inc.

Health Care · Biotechnology

$3.33

+3.33 (+0.00%)

Open

N/A

Day Range

$3.23 - $3.33

52W Range

$1.38 - $7.34

Volume

152K

Price History

Key Statistics

Market Cap

N/A

P/E Ratio

N/A

EPS

N/A

Dividend Yield

N/A

P/B Ratio

N/A

Payout Ratio

N/A

ROE

N/A

Debt/Equity

N/A

Latest News

Agenus (AGEN) Presents New Phase 1b Clinical Data on BOT/BAL Combination for MSS mCRC

Insider Monkey 4 days ago

Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL

Business Wire Feb 19, 2026

Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors

Business Wire Feb 9, 2026

LGND: New Year Program Updates

Zacks Small Cap Research Feb 3, 2026

Agenus Webcast: Zydus Manufacturing Deal Closes, France Access Expands, Phase 3 BATMAN Nears Launch

MarketBeat Jan 29, 2026

Peers in Health Care

Symbol Name Price Mkt Cap Div Yield Change
ABT Abbott Laboratories $116.35 N/A 2.06% +0.00%
ABUS Arbutus Biopharma Corporation $4.66 N/A - +0.00%
ABCL AbCellera Biologics Inc. $3.61 N/A - +0.00%
ACAD ACADIA Pharmaceuticals Inc. $24.56 N/A - +0.00%
ACB Aurora Cannabis Inc. $3.84 N/A - +0.00%
CRSP CRISPR Therapeutics AG $60.14 N/A - +0.00%
A Agilent Technologies, Inc. $121.38 N/A 0.82% +0.00%
ABBV AbbVie Inc. $232.08 N/A 2.87% +0.00%

Community Sentiment

Sign in to vote

0% Bullish 0% Neutral 100% Bearish

0 votes

Discussion (0)

Sign in to join the discussion

Loading comments...

About Agenus Inc.

Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract t; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

www.agenusbio.com →

Dividend Safety

Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.

50

Borderline

Based on 4 fundamental factors

Analysis Tools

Sign in for analysis tools

Share